Captrust Financial Advisors Acquires 5,489 Shares of Organon & Co. (NYSE:OGN)

Captrust Financial Advisors increased its stake in shares of Organon & Co. (NYSE:OGN) by 22.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,853 shares of the company’s stock after buying an additional 5,489 shares during the period. Captrust Financial Advisors’ holdings in Organon & Co. were worth $445,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after purchasing an additional 218,165 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after purchasing an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Organon & Co. by 1.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock worth $147,634,000 after acquiring an additional 136,760 shares in the last quarter. LSV Asset Management raised its stake in shares of Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock worth $112,274,000 after acquiring an additional 30,557 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Organon & Co. by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company’s stock worth $63,582,000 after purchasing an additional 12,110 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, CEO Kevin Ali bought 34,000 shares of the firm’s stock in a transaction on Monday, May 5th. The stock was acquired at an average price of $8.80 per share, with a total value of $299,200.00. Following the completion of the purchase, the chief executive officer now owns 282,731 shares of the company’s stock, valued at approximately $2,488,032.80. This trade represents a 13.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel Karp purchased 3,500 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was bought at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the completion of the transaction, the vice president now owns 46,669 shares in the company, valued at approximately $384,552.56. This represents a 8.11% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 102,345 shares of company stock valued at $902,430. 1.96% of the stock is currently owned by company insiders.

Organon & Co. Stock Performance

Shares of OGN stock opened at $9.00 on Tuesday. The stock has a fifty day moving average of $12.09 and a 200 day moving average of $14.24. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $23.10. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of 2.70, a PEG ratio of 0.90 and a beta of 0.75. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.13. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.53 billion. During the same quarter in the previous year, the company earned $1.22 earnings per share. Organon & Co.’s quarterly revenue was down 6.7% on a year-over-year basis. As a group, research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Monday, May 12th will be issued a $0.02 dividend. The ex-dividend date is Monday, May 12th. This represents a $0.08 dividend on an annualized basis and a yield of 0.89%. Organon & Co.’s dividend payout ratio (DPR) is 2.78%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Evercore ISI lowered Organon & Co. from an “outperform” rating to an “inline” rating in a research report on Friday, May 2nd. Morgan Stanley decreased their target price on shares of Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Piper Sandler dropped their price target on shares of Organon & Co. from $24.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. Finally, Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $18.00.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.